Episode
GLP-1 Drugs in Question | Montpelier News
- Published
- Jul 18, 2026
- Duration seconds
- 109
- Processing state
not_requested- Canonical source
- https://sources.thednn.ai/3e735e0ebefcbdde
Actions
POST https://stenobird.com/v1/public/podcasts/montpelier-news-today-2-min-new-the-daily-news-now-7598987/episodes/glp-1-drugs-in-question-montpelier-news/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/montpelier-news-today-2-min-new-the-daily-news-now-7598987/glp-1-drugs-in-question-montpelier-news.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
UVM Health Network is pulling coverage for GLP-1 weight-loss drugs, impacting hundreds of employees and saving nearly $19 million — but for users like Mike Popovitch, who lost 35 pounds in three weeks, it’s devastating news. As employers nationwide reassess ballooning prescription costs, the move reflects a growing trend to curb spending — even as research remains unclear on long-term savings. While diabetes and other medical uses stay covered, those relying on these drugs for weight loss now face steep out-of-pocket costs, forcing a painful choice between health and finances. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/3e735e0ebefcbdde